Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This sunscreen formulation, developed by Cosmetique Active International (a division of L'Oréal), is a topical agent designed to prevent hyperpigmentation induced by visible light (VL) and ultraviolet (UV) radiation. Unlike standard sunscreens that primarily target UVA and UVB, this product is specifically formulated to provide protection against high-energy visible light, which is known to cause more persistent and intense pigmentation in individuals with darker skin phenotypes. The formulation likely incorporates a blend of organic and inorganic filters, such as iron oxides, which act as a physical and chemical barrier to absorb, reflect, and scatter light across the broad spectrum. It is primarily indicated for the prevention of visible light-induced skin darkening and the management of pigmentary disorders like melasma and post-inflammatory hyperpigmentation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cosmetique Active International sunscreen.